Catheter Precision, Inc. (NYSEAMERICAN:VTAK) Stock Short Interest Declines 42.8%

Catheter Precision, Inc. (NYSEAMERICAN:VTAK) was the recipient of a significant decline in short interest in the month of September. As of September 15th, there was short interest totaling 228,199 shares, a decline of 42.8% from the August 31st total of 398,714 shares. Based on an average trading volume of 934,294 shares, the short-interest ratio is presently 0.2 days. Approximately 1.7% of the company’s shares are short sold.

Catheter Precision Stock Up 1.3%

NYSEAMERICAN:VTAK traded up $0.00 on Thursday, hitting $0.15. 244,492 shares of the stock were exchanged, compared to its average volume of 1,534,548. The stock has a fifty day moving average of $0.21 and a 200-day moving average of $0.68. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.18 and a current ratio of 0.19. Catheter Precision has a fifty-two week low of $0.13 and a fifty-two week high of $3.20.

Catheter Precision’s stock is scheduled to reverse split on the morning of Monday, October 5th. The 1-10 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Sunday, October 4th.

Catheter Precision (NYSEAMERICAN:VTAK) last issued its earnings results on Friday, August 14th. The company reported ($0.92) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($19.00) by $18.08. The business had revenue of $1.02 million during the quarter, compared to analysts’ expectations of $2.00 million. Catheter Precision had a negative return on equity of 37.53% and a negative net margin of 656.03%.

Catheter Precision Company Profile

Catheter Precision, Inc is a medical device company focused on developing technologies for electrophysiology procedures used to diagnose and treat cardiac arrhythmias. Its products are designed to support physicians during catheter-based cardiac procedures, particularly those involving ventricular arrhythmias.

The company’s portfolio includes the VIVO system, a noninvasive cardiac mapping platform intended to help physicians identify the origin of ventricular arrhythmias and plan catheter ablation procedures.